Cover Image

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Isabel Carbery, Oliver Todd, Christian P. Selinger
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
by: Cong Dai, et al.
Published: (2024)

Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy
by: Shamim Joudaki, et al.
Published: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
by: A. B. Fons, et al.
Published: (2026)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
by: A. B. Fons, et al.
Published: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
by: Jessica D. Lee, et al.
Published: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
by: Quinn Goddard, et al.
Published: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
by: Virginia Solitano, et al.
Published: (2024)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
by: Sanjay K. Murthy
Published: (2026)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
by: Fai Fai Ho, et al.
Published: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
by: Suprabhat Giri, et al.
Published: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
by: Bharati Kochar, et al.
Published: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
by: Jessica A. Fitzpatrick, et al.
Published: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
by: Cristina Rubín de Célix, et al.
Published: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
by: Chang Liu, et al.
Published: (2026)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
by: Anupam Kumar Singh, et al.
Published: (2026)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
by: Aurelien Amiot, et al.
Published: (2025)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
by: Purab Patel, et al.
Published: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
by: Christian Labenz, et al.
Published: (2026)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
by: Mathieu Uzzan, et al.
Published: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
by: Catherine Z. Tang, et al.
Published: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
by: Monica E. W. Derks, et al.
Published: (2025)

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study
by: Christy Riggott, et al.
Published: (2025)

Frailty Is Associated With All‐Cause and Acute Hospitalisations During 18 Months Follow‐Up in Older Patients With Inflammatory Bowel Disease
by: Anne B. Fons, et al.
Published: (2026)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
by: Ryan Yanzhe Lim, et al.
Published: (2026)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
by: Suprabhat Giri, et al.
Published: (2025)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
by: Brigida Barberio, et al.
Published: (2026)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
by: José Luis Rueda García, et al.
Published: (2026)

Letter: Addressing opioid exposure and associated harms in patients with IBD
by: Christian P. Selinger, et al.
Published: (2024)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
by: Nina Dominik, et al.
Published: (2024)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
by: Liang Jiao, et al.
Published: (2026)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
by: Nathan Grellier, et al.
Published: (2025)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort
by: Christy Riggott, et al.
Published: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
by: J. M. Schattenberg, et al.
Published: (2026)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
by: Pinelopi Arvaniti, et al.
Published: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
by: Juan Macias, et al.
Published: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
by: Maral Amangurbanova, et al.
Published: (2024)